Regulus Therapeutics Inc. (RGLS)
Jun 25, 2025 - RGLS was delisted (reason: acquired by Novartis)
8.16
+0.02 (0.25%)
Inactive · Last trade price on Jun 24, 2025

Regulus Therapeutics Stock Forecast

Stock Price Forecast

The 6 analysts with 12-month price forecasts for Regulus Therapeutics stock had an average target of $8.50, with a low estimate of $7.00 and a high estimate of $11.

Price Target: $8.50 (+4.17%)
Analyst Consensus: Buy

Price Target

TargetLowAverageMedianHigh
Price$7.00$8.50n/a$11
Change-14.22%+4.17%n/a+34.80%

Analyst Ratings

The average analyst rating for Regulus Therapeutics stock from 6 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.

Recommendation Trends

No data available
RatingOct 2026
Strong Buyn/a
Buyn/a
Holdn/a
Selln/a
Strong Selln/a
Totaln/a

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.92
from -0.82
EPS Next Year
-1.08
from -0.92
Fiscal YearFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
EPS
-4.50-3.24-1.86-1.58-0.82-0.92-1.08
No. Analysts
-----87

Revenue Forecast

Revenue20252026202720282029
Highn/an/a
Avgn/an/a
Lown/an/a

Revenue Growth

Revenue Growth20252026202720282029
High--
Avg--
Low--

EPS Forecast

EPS20252026202720282029
High-0.74-0.82
Avg-0.92-1.08
Low-1.12-1.24

EPS Growth

EPS Growth20252026202720282029
High--
Avg--
Low--